Silibinin loaded inhalable solid lipid nanoparticles for lung targeting
AIM: In the current study, efforts are being made to prepare Inhalable Silibinin loaded solid lipid nanoparticles (SLNs) with narrow size distribution with improved bioavailability.
METHODS: SLNs were formulated by high shear homogenisation method SLNs were characterised, including Differential Scanning Calorimetry (DSC), Fourier transform infra-red spectroscopy (FTIR), particle size analysis, entrapment efficiency with Aerodynamic behaviour. The MTT assay was performed against A549 cell line, to measure their anticancer cell activity with In vivo study.
RESULTS: Optimized formulation exhibited spherical surface with a mean particle size of 221 ± 1.251 nm, PI of 0.121 ± 0.081, zeta potential of -4.12 ± 0.744. Aerodynamic behaviour such as Mass median aerodynamic diameter (MMAD) and Geometric size distribution (GSD) were found to be 5.487 ± 0.072 and 2.321 ± 0.141 respectively proved formulation is suitable for inhalation. In vitro cellular efficacy against A549 cells, revealed that the optimised formulations were more effective and potent.
CONCLUSION: The Inhalable SLNs approach was successfully engineered and administered to the lungs safely without causing any problems.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 39(2022), 1 vom: 31. Jan., Seite 1-24 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patel, Priya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4RKY41TBTF |
|---|
| Anmerkungen: |
Date Completed 15.02.2022 Date Revised 01.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/02652048.2021.2002448 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333627504 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333627504 | ||
| 003 | DE-627 | ||
| 005 | 20231225222035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2021.2002448 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333627504 | ||
| 035 | |a (NLM)34825627 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patel, Priya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Silibinin loaded inhalable solid lipid nanoparticles for lung targeting |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2022 | ||
| 500 | |a Date Revised 01.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: In the current study, efforts are being made to prepare Inhalable Silibinin loaded solid lipid nanoparticles (SLNs) with narrow size distribution with improved bioavailability | ||
| 520 | |a METHODS: SLNs were formulated by high shear homogenisation method SLNs were characterised, including Differential Scanning Calorimetry (DSC), Fourier transform infra-red spectroscopy (FTIR), particle size analysis, entrapment efficiency with Aerodynamic behaviour. The MTT assay was performed against A549 cell line, to measure their anticancer cell activity with In vivo study | ||
| 520 | |a RESULTS: Optimized formulation exhibited spherical surface with a mean particle size of 221 ± 1.251 nm, PI of 0.121 ± 0.081, zeta potential of -4.12 ± 0.744. Aerodynamic behaviour such as Mass median aerodynamic diameter (MMAD) and Geometric size distribution (GSD) were found to be 5.487 ± 0.072 and 2.321 ± 0.141 respectively proved formulation is suitable for inhalation. In vitro cellular efficacy against A549 cells, revealed that the optimised formulations were more effective and potent | ||
| 520 | |a CONCLUSION: The Inhalable SLNs approach was successfully engineered and administered to the lungs safely without causing any problems | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a A549 | |
| 650 | 4 | |a Lung cancer | |
| 650 | 4 | |a histopathology | |
| 650 | 4 | |a inhalation delivery | |
| 650 | 4 | |a silibinin | |
| 650 | 4 | |a solid lipid nanoparticle | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Lipid Nanoparticles |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Silybin |2 NLM | |
| 650 | 7 | |a 4RKY41TBTF |2 NLM | |
| 700 | 1 | |a Raval, Mihir |e verfasserin |4 aut | |
| 700 | 1 | |a Airao, Vishal |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatt, Vaibhav |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Pranav |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d 1989 |g 39(2022), 1 vom: 31. Jan., Seite 1-24 |w (DE-627)NLM013098217 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:1 |g day:31 |g month:01 |g pages:1-24 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/02652048.2021.2002448 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 1 |b 31 |c 01 |h 1-24 | ||